231 related articles for article (PubMed ID: 19592649)
1. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation.
Gilson CR; Milas Z; Gangappa S; Hollenbaugh D; Pearson TC; Ford ML; Larsen CP
J Immunol; 2009 Aug; 183(3):1625-35. PubMed ID: 19592649
[TBL] [Abstract][Full Text] [Related]
2. An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig.
Pinelli DF; Wagener ME; Liu D; Yamniuk A; Tamura J; Grant S; Larsen CP; Suri A; Nadler SG; Ford ML
Am J Transplant; 2013 Nov; 13(11):3021-30. PubMed ID: 24007441
[TBL] [Abstract][Full Text] [Related]
3. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival.
Adams AB; Shirasugi N; Jones TR; Durham MM; Strobert EA; Cowan S; Rees P; Hendrix R; Price K; Kenyon NS; Hagerty D; Townsend R; Hollenbaugh D; Pearson TC; Larsen CP
J Immunol; 2005 Jan; 174(1):542-50. PubMed ID: 15611281
[TBL] [Abstract][Full Text] [Related]
4. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
5. Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.
Ohata J; Sakurai J; Saito K; Tani K; Asano S; Azuma M
Clin Exp Immunol; 2002 Jul; 129(1):61-8. PubMed ID: 12100023
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD40 therapy extends renal allograft survival in rhesus macaques.
Pearson TC; Trambley J; Odom K; Anderson DC; Cowan S; Bray R; Lin A; Hollenbaugh D; Aruffo A; Siadak AW; Strobert E; Hennigar R; Larsen CP
Transplantation; 2002 Oct; 74(7):933-40. PubMed ID: 12394833
[TBL] [Abstract][Full Text] [Related]
7. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation.
Molano RD; Berney T; Li H; Cattan P; Pileggi A; Vizzardelli C; Kenyon NS; Ricordi C; Burkly LC; Inverardi L
Diabetes; 2001 Feb; 50(2):270-6. PubMed ID: 11272136
[TBL] [Abstract][Full Text] [Related]
8. Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure.
Xu H; Huang Y; Chilton PM; Hussain LR; Tanner MK; Yan J; Ildstad ST
J Immunol; 2008 Nov; 181(9):6616-24. PubMed ID: 18941252
[TBL] [Abstract][Full Text] [Related]
9. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
[TBL] [Abstract][Full Text] [Related]
10. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization.
Xu H; Yan J; Huang Y; Chilton PM; Ding C; Schanie CL; Wang L; Ildstad ST
Blood; 2008 Mar; 111(6):3266-75. PubMed ID: 17827394
[TBL] [Abstract][Full Text] [Related]
11. Donor-Specific Regulatory T Cell-Mediated Immune Tolerance in an Intrahepatic Murine Allogeneic Islet Transplantation Model with Short-Term Anti-CD154 mAb Single Treatment.
Lee SJ; Kim HJ; Byun NR; Park CG
Cell Transplant; 2020; 29():963689720913876. PubMed ID: 32216448
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
13. Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants.
Qian Y; Dana MR
Cornea; 2002 Aug; 21(6):592-7. PubMed ID: 12131037
[TBL] [Abstract][Full Text] [Related]
14. CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
Liu H; Qiu F; Wang Y; Zeng Q; Liu C; Chen Y; Liang CL; Zhang Q; Han L; Dai Z
Front Immunol; 2019; 10():306. PubMed ID: 30863408
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade.
Pilat N; Klaus C; Schwarz C; Hock K; Oberhuber R; Schwaiger E; Gattringer M; Ramsey H; Baranyi U; Zelger B; Brandacher G; Wrba F; Wekerle T
Am J Transplant; 2015 Jun; 15(6):1568-79. PubMed ID: 25783859
[TBL] [Abstract][Full Text] [Related]
16. IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in mice.
Lee JH; Ha J; Kim SH; Kim SJ
J Korean Med Sci; 2006 Dec; 21(6):1005-11. PubMed ID: 17179677
[TBL] [Abstract][Full Text] [Related]
17. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
[TBL] [Abstract][Full Text] [Related]
18. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion.
Cordoba F; Wieczorek G; Audet M; Roth L; Schneider MA; Kunkler A; Stuber N; Erard M; Ceci M; Baumgartner R; Apolloni R; Cattini A; Robert G; Ristig D; Munz J; Haeberli L; Grau R; Sickert D; Heusser C; Espie P; Bruns C; Patel D; Rush JS
Am J Transplant; 2015 Nov; 15(11):2825-36. PubMed ID: 26139432
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
20. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.
Prigozhina TB; Gurevitch O; Elkin G; Morecki S; Yakovlev E; Slavin S
Exp Hematol; 2003 Jan; 31(1):81-8. PubMed ID: 12543110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
